Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer.
Biologic response
Neoadjuvant chemotherapy
Pancreatic ductal adenocarcinoma
Pathologic response
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
28
06
2022
accepted:
16
09
2022
medline:
6
4
2023
pubmed:
25
10
2022
entrez:
24
10
2022
Statut:
ppublish
Résumé
The role of postoperative chemotherapy in patients with resected pancreatic cancer who receive neoadjuvant treatment is unknown. Clinicians use changes in CA19-9 and histopathologic scores to assess treatment response. We sought to investigate if CA19-9 normalization in response to NAT can help guide the need for postoperative treatment. Patients with elevated baseline CA19-9 (CA19-9 > 37U/mL) who received NAT followed by surgery between 2011 and 2019 were retrospectively reviewed. Treatment response was determined by CA19-9 normalization following NAT and histopathologic scoring. The role of postoperative chemotherapy was analyzed in light of CA19-9 normalization and histopathologic response. We identified and included 345 patients. Following NAT, CA19-9 normalization was observed in 125 patients (36.2%). CA19-9 normalization was associated with a favorable histopathologic response (41.6% vs 23.2%, p < 0.001) and a lower ypT (p < 0.001) and ypN stage (p = 0.003). Receipt of adjuvant chemotherapy was associated with improved overall survival in patients in whom CA19-9 did not normalize following NAT (26.8 vs 16.4 months, p = 0.008). In patients who received 5FU-based NAT and in whom CA19-9 did not normalize, receipt of 5FU-based adjuvant chemotherapy was associated with improved OS (p = 0.014). CA19-9 normalization in response to NAT was associated with favorable outcomes and can serve as a biomarker for treatment response. In patients where CA19-9 did not normalize, receipt of postoperative chemotherapy was associated with improved OS. These patients also benefited from additional 5FU-based postoperative chemotherapy following 5FU-based NAT.
Sections du résumé
BACKGROUND
The role of postoperative chemotherapy in patients with resected pancreatic cancer who receive neoadjuvant treatment is unknown. Clinicians use changes in CA19-9 and histopathologic scores to assess treatment response. We sought to investigate if CA19-9 normalization in response to NAT can help guide the need for postoperative treatment.
METHODS
Patients with elevated baseline CA19-9 (CA19-9 > 37U/mL) who received NAT followed by surgery between 2011 and 2019 were retrospectively reviewed. Treatment response was determined by CA19-9 normalization following NAT and histopathologic scoring. The role of postoperative chemotherapy was analyzed in light of CA19-9 normalization and histopathologic response.
RESULTS
We identified and included 345 patients. Following NAT, CA19-9 normalization was observed in 125 patients (36.2%). CA19-9 normalization was associated with a favorable histopathologic response (41.6% vs 23.2%, p < 0.001) and a lower ypT (p < 0.001) and ypN stage (p = 0.003). Receipt of adjuvant chemotherapy was associated with improved overall survival in patients in whom CA19-9 did not normalize following NAT (26.8 vs 16.4 months, p = 0.008). In patients who received 5FU-based NAT and in whom CA19-9 did not normalize, receipt of 5FU-based adjuvant chemotherapy was associated with improved OS (p = 0.014).
CONCLUSION
CA19-9 normalization in response to NAT was associated with favorable outcomes and can serve as a biomarker for treatment response. In patients where CA19-9 did not normalize, receipt of postoperative chemotherapy was associated with improved OS. These patients also benefited from additional 5FU-based postoperative chemotherapy following 5FU-based NAT.
Identifiants
pubmed: 36280632
doi: 10.1007/s11605-022-05476-w
pii: 10.1007/s11605-022-05476-w
pmc: PMC10079604
mid: NIHMS1880356
doi:
Substances chimiques
CA-19-9 Antigen
0
Fluorouracil
U3P01618RT
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
691-700Subventions
Organisme : NCI NIH HHS
ID : P01 CA247886
Pays : United States
Informations de copyright
© 2022. The Society for Surgery of the Alimentary Tract.
Références
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26580-26590
pubmed: 31818951
Ann Surg Oncol. 2010 Jul;17(7):1794-801
pubmed: 20162463
Ann Surg. 2014 Aug;260(2):372-7
pubmed: 24374509
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Clin Cancer Res. 2021 Feb 1;27(3):740-748
pubmed: 33082211
Mod Pathol. 2021 Jan;34(1):4-12
pubmed: 33041332
Cancer Discov. 2018 Sep;8(9):1112-1129
pubmed: 29853643
Pancreas. 2019 Jul;48(6):837-843
pubmed: 31210666
J Clin Oncol. 2008 Jul 20;26(21):3487-95
pubmed: 18640929
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
J Gastrointest Oncol. 2013 Dec;4(4):361-9
pubmed: 24294507
HPB (Oxford). 2014 May;16(5):430-8
pubmed: 23991810
Nature. 2010 Oct 28;467(7319):1114-7
pubmed: 20981102
Ann Surg. 2020 Apr;271(4):740-747
pubmed: 30312198
J Clin Oncol. 2022 Apr 10;40(11):1220-1230
pubmed: 35084987
J Gastrointest Surg. 2018 Feb;22(2):214-225
pubmed: 29235000
Ann Surg Oncol. 2022 Apr;29(4):2720-2731
pubmed: 34792696
Surgery. 2022 May;171(5):1379-1387
pubmed: 34774289
Ann Surg Oncol. 2014 Sep;21(9):2873-81
pubmed: 24770680
Front Oncol. 2020 Feb 28;10:245
pubmed: 32185128
J Clin Oncol. 2017 Jul 10;35(20):2324-2328
pubmed: 28398845
Ann Surg Oncol. 2022 Mar;29(3):1579-1591
pubmed: 34724125
Cancer. 2012 Jun 15;118(12):3182-90
pubmed: 22028089
Cancer. 2013 Jan 15;119(2):285-92
pubmed: 22786786
Ann Surg. 2018 May;267(5):936-945
pubmed: 28338509
Ann Surg Oncol. 2020 Oct;27(10):3950-3960
pubmed: 32318949
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Ann Surg Oncol. 2014 Dec;21(13):4351-8
pubmed: 25092157